Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Raised by Caligan Partners LP

Caligan Partners LP grew its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 31.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 981,155 shares of the company's stock after buying an additional 235,397 shares during the quarter. Mineralys Therapeutics accounts for approximately 3.8% of Caligan Partners LP's holdings, making the stock its 9th largest position. Caligan Partners LP owned approximately 1.97% of Mineralys Therapeutics worth $11,882,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Mineralys Therapeutics by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 982,932 shares of the company's stock worth $12,690,000 after purchasing an additional 4,952 shares during the period. Bank of New York Mellon Corp raised its position in Mineralys Therapeutics by 72.5% in the second quarter. Bank of New York Mellon Corp now owns 84,762 shares of the company's stock worth $992,000 after acquiring an additional 35,634 shares during the period. Rhumbline Advisers raised its position in Mineralys Therapeutics by 82.1% in the second quarter. Rhumbline Advisers now owns 41,079 shares of the company's stock worth $481,000 after acquiring an additional 18,519 shares during the period. American Century Companies Inc. boosted its stake in shares of Mineralys Therapeutics by 3.2% during the 2nd quarter. American Century Companies Inc. now owns 743,140 shares of the company's stock worth $8,695,000 after acquiring an additional 23,170 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in shares of Mineralys Therapeutics by 100.0% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $140,000 after acquiring an additional 6,000 shares during the period. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a report on Tuesday, November 12th.

Mineralys Therapeutics Trading Down 2.6 %

Mineralys Therapeutics stock traded down $0.34 during midday trading on Friday, hitting $12.77. The stock had a trading volume of 104,020 shares, compared to its average volume of 242,229. Mineralys Therapeutics, Inc. has a 52-week low of $6.38 and a 52-week high of $16.91. The company has a market capitalization of $635.56 million, a PE ratio of -3.91 and a beta of 1.71. The firm's fifty day moving average is $13.15 and its two-hundred day moving average is $12.57.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings data on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.30). During the same period in the previous year, the firm earned ($0.57) EPS. As a group, equities research analysts predict that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Adam Scott Levy sold 10,757 shares of the company's stock in a transaction on Friday, October 11th. The shares were sold at an average price of $13.57, for a total transaction of $145,972.49. Following the completion of the transaction, the chief financial officer now owns 236,854 shares in the company, valued at approximately $3,214,108.78. This represents a 4.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Malcom Rodman sold 25,482 shares of Mineralys Therapeutics stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the sale, the insider now owns 135,974 shares in the company, valued at approximately $2,043,689.22. This represents a 15.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,510 shares of company stock worth $735,431. Corporate insiders own 33.24% of the company's stock.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.